Loading...
Market
What will be Travere Therapeutics' stock price at the end of 2024?
2
Resolution / Starting Odds
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Stock price data from a reliable financial news source such as Bloomberg or Yahoo Finance
Story
FDA Grants Full Approval to Travere Therapeutics' FILSPARI for IgA Nephropathy, Stock Rises 5.7%
Sep 6, 2024, 01:22 PM
The FDA has granted full approval to Travere Therapeutics' drug FILSPARI (sparsentan), marking it as the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgA nephropathy (IgAN). This approval follows a conversion from an accelerated approval and comes with an expanded label. The decision has positively impacted Travere's stock, which saw a 5.7% increase in pre-market trading. The approval is expected to intensify competition with Novartis and Calliditas in the kidney disease treatment market. Ligand Partner is also associated with this approval.
View original story
Similar markets
Up more than 10% • 25%
Up between 5% and 10% • 25%
Up less than 5% • 25%
Down • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Less than $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
More than $40 • 25%
Above $25 • 25%
$20 - $25 • 25%
$15 - $20 • 25%
Below $15 • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Below $2 • 25%
$2 to $5 • 25%
Above $10 • 25%
Below $5 • 25%
$5 to $10 • 25%
$10 to $15 • 25%
Above $15 • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Below $150 • 25%
$150 - $175 • 25%
$175 - $200 • 25%
Above $200 • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%